ADC Therapeutics (ADCT) Cash from Investing Activities (2023 - 2026)
ADC Therapeutics' (ADCT) quarterly Cash from Investing Activities came in at -$32000.0 in Q1 2026, up 87.88% year-on-year from -$17032.3 in Q1 2025, and down 104.86% quarter-over-quarter from $659000.0 in Q4 2025.
ADC Therapeutics (ADCT) Cash from Investing Activities (2023 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Cash from Investing Activities across 4 years of filings, most recently posting -$32000.0 for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$32000.0, up 87.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $627000.0 (up 204.5% YoY), and the FY2025 annual result was $395000.0, up 145.56% from the prior year.
- Cash from Investing Activities came in at -$32000.0 for Q1 2026 at ADC Therapeutics, down from $659000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $659000.0 in Q4 2025 to a low of -$1.2 million in Q2 2023.
- The 4-year median for Cash from Investing Activities is -$264000.0 (2025), against an average of -$338181.8.
- Across the five-year window, Cash from Investing Activities jumped 47.74% in 2024 and soared 832.22% in 2025, its largest moves.
- ADC Therapeutics' Cash from Investing Activities stood at -$327000.0 in 2023, then soared by 72.48% to -$90000.0 in 2024, then jumped by 832.22% to $659000.0 in 2025, then slumped by 104.86% to -$32000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$32000.0 (Q1 2026), $659000.0 (Q4 2025), and -$264000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn | -32,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32,000.00 |
| Mar 31, 2026 | -32,000.00 |
| Dec 31, 2025 | 659,000.00 |
| Dec 31, 2025 | 659,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Dec 31, 2024 | -90,000.00 |
| Dec 31, 2024 | -90,000.00 |
| Sep 30, 2024 | -216,000.00 |
| Sep 30, 2024 | -216,000.00 |
| Jun 30, 2024 | -30,000.00 |
| Jun 30, 2024 | -30,000.00 |
| Mar 31, 2024 | -531,000.00 |
| Mar 31, 2024 | -531,000.00 |
| Dec 31, 2023 | -327,000.00 |
| Dec 31, 2023 | -327,000.00 |
| Sep 30, 2023 | -661,000.00 |
| Sep 30, 2023 | -661,000.00 |
| Jun 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | -1.21 Mn |